alexa
Reach Us +1-217-403-9671
Regulatory Frame Work For Biosimilar Monoclonal Antibodies | 7538
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Regulatory frame work for biosimilar monoclonal antibodies

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

K. Sreekanth Reddy

Accepted Abstracts: Pharmaceut Reg Affairs

DOI: 10.4172/2167-7689.S1.008

Abstract
The objective of this paper is to facilitate regulatory requirements for the approval process of Biosimilar Monoclonal antibodies (mAb) in Regulated and Emerging markets. Biosimilars are biological products that are the replicas of their innovator biopharmaceuticals. Monoclonal antibodies have been established as a major product class of biotechnology-derived medicinal products. Specified regulations, and approval process of generic version of mAb exists depending on the country. In European Union, Centralized Procedure is mandatory for Biosimilar (mAb). When compared with other countries EMA (European medicines agency) has proper regulations pertaining to Biosimilar mAbs. In US proper set of guidelines for Biosimilar (mAb) have evolved after ?Promoting Innovation and Access to life-saving Medicines Act? introduced, authorized USFDA to approve followon biologics/biosimilars in an abbreviated manner. The approval process is abbreviated biosimilar biologics license applications (bBLAs) or 351(k) filings. In India, the product is under new drugs, and follows the Biological drugs submission requirements. In India, apart from Central Drugs Standard Control Organization (CDSCO), the office of Drug Controller General of India (DCGI) the apex regulatory body under Government of India (GoI), two other competent authorities are involved in the approval process of biosimilars or Similar Biologics products (SBPs). It is a big difficulty to Biosimilar mAb potential producers to fallow different approval processes and regulations in different regions. This paper concludes that there is a need that ICH/WHO should come forward and lay down proper and specific regulations for these products.
Biography
I K.Sreekanth Reddy, studying m.ph first year regulatory affairs in jsscp, Mysore. I completed my B.ph at Victoria College of pharmacy, Guntur .I given poster presentation on 63rd IPC held at Bangalore.
Top